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 Clinical Standards Committee  
The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) is a 
scientiﬁc organization that encourages sound clinical practice, teaching and research for 
diagnostic imaging in women’s healthcare. The ISUOG Clinical Standards Committee 
(CSC) has a remit to develop Practice Guidelines and Consensus Statements as 
educational recommendations that provide healthcare practitioners with a consensus-
based approach for diagnostic imaging. They are intended to reﬂect what is considered 
by ISUOG to be the best practices at the time at which they are issued. Although ISUOG 
has made every effort to ensure that guidelines are accurate when issued, neither the 
Society nor any of its employees or members accepts any liability for the consequences 
of any inaccurate or misleading data, opinions or statements issued by the CSC. They 
are not intended to establish a legal standard of care because interpretation of the 
evidence that underpins the guidelines may be inﬂuenced by individual circumstances 
and available resources. 
 
 
 
INTRODUCTION 
 
Hypertensive disease of pregnancy affects up to 10% of pregnant women 
1
 and the 
pooled global incidence of preeclampsia is approximately 3% 
2
. Significant variations 
between developed and developing countries can be attributed to actual and 
methodological reasons. Preeclampsia and its complications are a major contributor to 
maternal and perinatal morbidity and mortality worldwide 
1 3
. Given that timely and 
effective care can improve the outcome of preeclampsia 
3
, the development of effective 
prediction and prevention strategies has been a major objective of prenatal care and of 
research. 
Preeclampsia is a multisystemic disease of multifactorial origin: it involves defective 
placentation, oxidative stress, autoimmunity, platelet and thrombin activation, 
intravascular inflammation, endothelial dysfunction, an imbalance in angiogenesis and 
maternal cardiac maladaptation 
4 5
. Defective placental invasion is strongly associated 
with most cases of early and severe preeclampsia 
4
.  
In contrast, defective placentation seems to be less important for the development of 
preeclampsia that manifests later in pregnancy, e.g. after 34 weeks. Placentas from 
pregnancies complicated with preeclampsia at or near term have a significantly lower 
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frequency of histological abnormalities compared to early-onset disease 
6
 and maternal 
factors (e.g. metabolic syndrome or chronic hypertension) have a relatively greater 
significance 
4
. Differences in early- and late-onset preeclampsia are also seen in risk 
factors 
7
, maternal vascular responsiveness 
8
, screening performance 
9
 and prevention 
effectiveness 
10
. 
Increasing insight in these mechanisms has been reflected in the current screening 
strategies, which are based on four arms, i.e. maternal history, maternal demographics, 
uterine artery Doppler studies and biomarkers, including maternal blood pressure 
11
. 
There are currently more than 10,000 PubMed-indexed articles related to preeclampsia 
screening, by any tests and modalities, illustrating the vast interest on this topic. Less 
than one-fifth of these refer to early screening, as this is a development of the last 
decade. The aim of this guideline is to review latest evidence and provide evidence-
based recommendations, when possible, on the role of ultrasound in screening and 
follow-up of pre-eclampsia. The guideline intends to focus on the technical / clinical 
aspects of screening, without extending to health economics and policy issues, including 
the advisability and cost-effectiveness of screening. Moreover, this guideline was built 
under the assumption that the resources required for its implementation (equipment, 
examiners, expertise) are available. Therefore, the steps and procedures described in 
this Guideline are not intended to act as a legal standard for clinical service. 
 
TERMINOLOGY: SCREENING vs. PREDICTION 
 
Although the two terms are commonly used interchangeably, screening is in fact a wider 
process, beginning with invitation of a population to participate and ending with treatment 
for individuals identified at high risk 
12
. In this context, prediction, or the calculation of risk 
for disease, is an integral element of the screening process, but it is not equivalent with 
screening, as the latter also involves an intervention that is offered to individuals at high 
risk and aims to alter the natural history of the condition screened for, and ultimately to 
improve the outcome 
13
. Screening in prenatal care has been commonly used for offering 
the option of timely termination of pregnancy to parents bearing fetuses with untreatable 
conditions, which is an extension to the WHO principles of screening. In the context of 
preeclampsia, screening will be the preferred term when identification of cases at risk 
may lead to prevention of its development, whereas prediction will be the preferred term 
when there is no evidence that identification of women at risk will eventually improve 
their outcome.  
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RELEVANT INFORMATION AVAILABLE TO THE EXAMINER  
Recommendation 
• Examiners involved in screening for preeclampsia should have up-to-date 
knowledge regarding major risk factors for preeclampsia  
 
GPP 
Given that ultrasound screening for preeclampsia should not be isolated from the general 
concept of prenatal care, it is advisable that professionals who screen for preeclampsia 
have up-to-date knowledge about proven risk factors and engage at identifying them 
during screening. A global assessment of risk profile would encompass four broad areas, 
i.e. personal risk profile (including age, ethnicity, parity, smoking, medical and obstetric 
history and conception method), metabolic risk profile (including BMI and history of 
diabetes), cardiovascular risk profile (including existing cardiovascular conditions and 
measurement of mean arterial blood pressure) and placental risk profile (including 
uterine artery Doppler and maternal serum biomarkers) 
11
.  
 
SCREENING FOR PREECLAMPSIA USING ULTRASOUND  
The use of ultrasound as a screening / prediction tool for preeclampsia is based on the 
fact that defective placentation results in incomplete transformation of the spiral arteries. 
The latter phenomenon is quantifiable through measurement of impedance (or 
resistance) to flow in the uterine arteries by Doppler assessment. Placental villous and 
vascular histopathological lesions are four-to-seven times more common in preeclamptic 
pregnancies 
14
 and are associated with increased resistance to uterine artery blood flow 
15
. 
 
Which Doppler index to use  
Recommendation 
• The pulsatility index (PI) is the index that should be used for the examination of 
the uterine artery resistance in the context of preeclampsia screening 
 
 
Grade: B 
As described in the ISUOG Practice Guideline on the use of Doppler ultrasonography in 
obstetrics 
16
, systolic-diastolic (S/D) ratio, resistance index (RI) and pulsatility index (PI) 
are the three well-known indices to describe arterial flow velocity waveforms. The 
pulsatility index is the most commonly used index; its advantage over RI in the 
evaluation of the uterine artery Doppler waveform is that PI includes in the 
calculation the averaged value of all maximum velocities during the cardiac cycle 
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instead of only two moments in the cardiac cycle as it is in the resistance index. 
Pulsatility index is more stable and it does not approach infinity when there are absent 
or reversed diastolic values 
16
. 
Uterine artery notching has also been used in screening for preeclampsia 
17
, with the 
presence of bilateral notches being associated with indications of maternal endothelial 
dysfunction (lower flow-mediated dilatation of the brachial artery)
18
. Despite its 
theoretical plausibility, bilateral notching is anyway common (43%) in normal first-
trimester pregnancies
19
, which reduces its specificity as a screening marker. Similarly, 
the presence of uterine artery notches in the second trimester has similar sensitivity to 
that of increased PI, but for a higher screen positive rate 
17
, and there may be a degree 
of subjectivity in defining notching, which further limits the value of this finding as a 
screening marker.  
A 2008 meta-analysis indicated that an increased pulsatility index, alone or combined 
with notching, is the most predictive Doppler index for preeclampsia 
20
. A considerable 
amount of evidence published since then indicates the superiority of mean uterine PI as 
the preferred Doppler index for preeclampsia screening, and this is the index tested for 
screening and prevention in the first trimester
21-23
. 
First trimester  
Technical advice 
• Doppler examination of the uterine arteries at 11
+0
 – 13
+6
 weeks can be 
performed either transabdominally or transvaginally, according to local 
conditions and resources 
• Screening by first-trimester uterine artery PI above the 90
th
 centile detects 48% 
of women who will develop early preeclampsia and 26% of any preeclampsia for 
a 10% screen positive rate 
 
 
GPP 
 
 
Level of 
evidence: 
2++ 
Technique of first-trimester Doppler examination of the uterine arteries. 
The most extensively studied period of Doppler examination of the uterine arteries is at 
11
+0
 to 13
+6
 weeks. This is a common time for first trimester ultrasound in many countries 
and therefore practical in terms of logistics. Earlier assessment has not been sufficiently 
studied because trophoblast invasion is not yet advanced as to be assessable. 
For the first-trimester assessment of uterine artery resistance, a transabdominal 
midsagittal section of the uterus and cervix is initially taken. Using color flow mapping, 
the transducer is gently tilted sideways, so that the uterine arteries are identified as a 
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high-velocity blood flow vessel along the side of the cervix and uterus. The sampling 
gate of pulsed wave (PW) Doppler is narrow (e.g. set at 2 mm) of either the ascending or 
descending branch of the uterine artery at the point closest to the internal cervical os, 
with an insonation angle of less than 30° 
24
. The peak systolic velocity should be >60 
cm/sec in order to verify that the uterine artery is examined. The PI is measured when 3 
similar waveforms are obtained 
25 26
. The rationale for using this particular methodology 
is that it has been standardized, and underlies most of the first-trimester screening 
studies. Detailed methodology can be found in a practical advice paper published in the 
ISUOG’s journal 
27
. Following this approach, uterine artery PI can be measured in more 
than 95% of the cases 
25
 (Figure 1).   
The transvaginal measurement follows the same principles. The woman is placed in the 
lithotomy position, with her bladder empty, and a transvaginal probe is used to obtain a 
sagittal view of the cervix. The probe is then moved laterally until the paracervical 
vascular plexus is seen, and the uterine artery is identified at the level of the internal 
cervical os. Measurements are taken after it is ensured that the angle of insonation is 
≤30° 
28
. 
 
Technical advice 
• A standard methodology, as described in the guideline, should be followed for 
the examination of the uterine artery Doppler indices 
 
 
GPP 
Adherence to a standard methodology is essential to ensure reproducible 
measurements. Studies evaluating the reproducibility of this technique have shown 
interobserver intraclass/concordance correlation coefficients of 0.80-0.85  
29 30
. However, 
the limits of agreement were found be as high as ±35% for the transvaginal and ±40% 
for the transabdominal approach 
30
. Based on such results, the reproducibility of the 
method should be interpreted as being poor to moderate 
31
. Besides differences caused 
by observers, Doppler indices may change over the span of an examination, owing to 
factors such as uterine contractions, different heart rate, etc. Although the effect of these 
latter factors cannot be prevented, adherence to the standard methodology of 
examination
27
 is imperative to minimize the operator-dependent variability, as systematic 
error in the measurements can affect screen-positive rate 
32
. 
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Technical advice 
• The 95
th
 centile for transabdominal uterine artery mean PI between 11+0 and 
13+6 weeks is 2.35 
• The resistance of the uterine arteries is higher in transvaginal compared to 
transabdominal measurement; the 95
th
 centile of the measurable mean 
resistance (PI) values of the uterine arteries is approximately 3.10 for CRL up to 
65 mm, gradually declining thereafter 
• The uterine artery PI may also be affected by maternal factors, including ethnic 
origin, BMI and previous preeclampsia 
Recommendation 
• Given that maternal factors can affect uterine artery PI, whenever feasible, 
inclusion of uterine artery PI in a multifactorial screening model should be 
preferred over its use as a standalone test with absolute cut-offs 
 
Level of 
evidence: 2+ 
 
Level of 
evidence: 2+ 
 
 
Level of 
evidence: 
2++ 
 
 
 
 
Grade: B 
The 95
th
 centile of mean uterine artery PI with the transabdominal approach is about 
2.35 for the period of 11+0 to 13+6 weeks 
25
, with no- 
25
 or only a small trend to decrease 
30
 over this period. In two comparative studies, transvaginal approach gave significantly 
higher readings compared to the transabdominal one; the mean PIs in the two studies 
were 1.98 vs. 1.83 
33
, and 1.60 vs. 1.52 
30
. The reason for this may be that TVS ensures 
a closer proximity to the vessel and lower insonation angles 
30
 . The 95
th
 centile of the 
mean UtA PI for transvaginal measurements has been reported as approximately 3.10 
for CRL up to 65 mm and progressively declines thereafter, reaching 2.36 at a CRL of 84 
mm 
33
. 
Maternal factors may affect uterine artery PI in women not developing preeclampsia, 
including ethnic origin (African is associated with increased PI), BMI (decreases with 
increasing BMI) and previous preeclampsia (associated with increased PI) 
26
. The 
association between decreasing PI and increasing BMI is not clear; the vasodilatory 
effect of increased levels of estrogens in these women on the uterine circulation has 
been postulated as a potential cause 
26 34
. Therefore, an absolute numerical cut-off for 
uterine artery PI may not accurately reflect uterine arteries resistance, and it has been 
suggested that first-trimester uterine artery PI should be expressed as multiples of the 
median (MoMs) rather than as absolute values 
35
 
 
 
Recommendation 
• The mean uterine artery PI should be the Doppler index used for screening in 
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the first trimester Grade: B 
In one of the earlier studies using the current standard methodology for the examination 
of uterine artery Doppler in the first trimester, a PI >95
th
 centile had 27% sensitivity for 
preeclampsia and 60% sensitivity for preeclampsia requiring delivery before 32 weeks 
25
. 
Subsequent studies used lowest uterine artery PI (the PI of the side with the least 
resistance), as the point estimates for the area under the curve (AUC) were marginally 
better when the lowest rather than the mean PI was used in the regression model (0.91 
vs. 0.90 for early preeclampsia) 
36
. However, the confidence intervals for the AUCs were 
overlapping, and the superiority of the lower PI was not confirmed by another large study 
(AUC 0.79 for mean and 0.76 for lowest PI for the outcome of early preeclampsia, with 
overlapping CIs) 
37
. Both techniques are acceptable, but the mean uterine artery PI is the 
most commonly used index for first- and second-trimester uterine artery Doppler 
examination, and the default reference values in most commercial software apply to this.  
Although bilateral notching has been associated with 22-fold increased risk for 
preeclampsia and almost 9-fold increased risk for small-for-gestational age neonate 
38
, it 
can be found in more than 50% of women at 11+0 to 13+6 weeks 
25 39
. Therefore, this 
marker has a very low specificity for preeclampsia.  
A recent meta-analysis reported that first-trimester Doppler examination of the uterine 
arteries can predict 47.8% of early preeclampsia (7.9% false positive rate), 39.2% of 
early fetal growth restriction (6.7% false positive rate) and 26.4% of any preeclampsia 
(6.6% false positive rate), when using the 90
th
 centile of PI or RI as cut-off 
40
. 
However, combined screening (maternal factors, maternal mean arterial blood pressure, 
uterine arteries Doppler, PlGF measurement) has superior predictive performance 
(please see at the relevant section) and should be preferred over Doppler-based 
screening, if available.  
 
 
Second trimester 
 
 
Technical advice 
• Doppler examination of the uterine arteries can be performed either 
transabdominally or transvaginally, according to the local conditions and 
resources 
 
 
GPP 
Uterine artery flow resistance can be assessed either transabdominally or transvaginally.  
Page 8 of 42
John Wiley & Sons, Ltd.
Ultrasound in Obstetrics and Gynecology
For Peer Review
9 
 
The transabdominal technique is similar to that of the first trimester, the main difference 
being that right and left uterine arteries are identified at the apparent crossover with the 
external iliac arteries rather than paracervically. After the arteries are identified, pulsed-
wave Doppler is used to obtain the waveforms. When three similar consecutive 
waveforms are obtained, the pulsatility index (PI) is measured, and the presence or 
absence of early diastolic notch is recorded 
41
. 
In the transvaginal technique, the woman is asked to empty her bladder and is placed in 
the dorsal lithotomy position. The ultrasound probe is inserted into the anterior fornix, 
and the cervix is identified in the midsagittal plane. Subsequently, the probe is moved 
into the lateral fornix and the uterine artery is identified using color Doppler at the level of 
the internal cervical os on either side. Pulsed wave Doppler is used to obtain three 
similar consecutive waveforms. The pulsatility and resistance index can then be 
measured and the presence or absence of early diastolic notch can be recorded 
17
. The 
examination of uterine artery Doppler waveform following this approach is feasible in 
99% of women 
42
.  
As in the first trimester, using either transabdominal or transvaginal approach, care 
should be taken to maintain the angle of insonation <30° and the peak systolic velocity 
>60 cm/sec to ensure that the uterine artery rather than the arcuate artery is being 
examined 
24
.  
 
Technical advice 
• As in the first trimester, uterine artery PI in the second trimester is higher when 
measured transvaginally 
• The 95
th
 centile for mean uterine artery PI is 1.44 for the transabdominal 
approach and 1.58 for the transvaginal approach at 23 weeks. 
• The 95
th
 centile for the mean uterine artery PI decreases by about 20% between 
20 and 24 weeks, and it does not change significantly between 22-24 weeks 
 
Recommendation 
• The mean uterine artery PI may be used for prediction of preeclampsia. In case 
of a unilateral placenta, a unilaterally increased PI does not appear to increase 
the risk for preeclampsia if the mean PI is within normal limits. 
 
 
Level of 
evidence: 
2++ 
Level of 
evidence: 2+ 
Level of 
evidence: 
2++ 
 
 
 
Grade: B 
Similarly to first trimester, when the uterine arteries are examined transvaginally, the PI 
readings are higher compared to the transabdominal approach. In a comparative series 
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of 96 women between 20 and 26 weeks, the mean UtA PI was 1.07 with the transvaginal 
vs. 0.96 with the transabdominal approach. The median angle of insonation was lower 
using TVS (10.0° vs. 17.5°); however, PI being a ratio, the most likely reason for the 
differences between transabdominal and transvaginal differences is the different 
anatomical location of the examination. Both techniques have similar reproducibility 
(interobserver concordance coefficient 0.86 vs. 0.81, limits of agreement ±35%) 
30
. 
The 95
th
 centile of the mean UtA PI with the transabdominal approach has been reported 
as 1.44 
41
 whereas the corresponding value for the transvaginal approach was 1.58 
43
 at 
23 weeks. The 95
th
 centile of the mean uterine artery PI decreases by about 15% 
between 20 and 24 weeks, and by <10% between 22-24 weeks 
44
.  
In case of a unilaterally localized placenta, the resistance to the uterine flow opposite to 
the placenta is commonly increased. A unilaterally increased PI does not appear to be 
associated with a higher risk for preeclampsia, if the mean PI is within normal limits 
45
. 
 
Performance of second-trimester prediction of preeclampsia  
The predictive performance of uterine artery Doppler is preferentially higher for early-
onset preeclampsia; a study of more than 32,000 women indicated that, for a false 
positive rate of 10%, UtA PI alone can predict 85% of the cases of early-onset 
preeclampsia, vs. 48% of late-onset preeclampsia when combined with maternal factors 
46
. Furthermore, the risk for early preeclampsia appears to increase with increasing UtA 
resistance; a mean PI of 1.6 was associated with a LR of 3.07, vs. LR 8.00 for a mean PI 
of 1.8 and LR 27.08 for mean PI 2.2 (transvaginal measurements). In general, the UtA 
Doppler velocimetry tends to predict better more severe and complicated cases. For 
example, mean PI>1.65 (TVS) was found to predict 41% of all preeclampsia cases, but 
when subgroups were examined, this rate was 69% for preeclampsia with fetal growth 
restriction vs. 24% for preeclampsia with normal fetal growth 
17
. This finding can be 
explained by the fact that high impedance in the uterine arteries reflects defective 
placentation, with its concomitant deleterious effect on fetal growth. 
Bilateral diastolic notches in the UtA Doppler waveform are also associated with 
increased risk for preeclampsia 
17 41 42 46 47
. However, for the same false positive rate, UtA 
PI is associated with better sensitivity than notches 
42
, making their addition to screening 
not recommendable, although not all studies agree on the latter 
47
. 
In terms of maternal health, a study of 491 women undergoing transthoracic 
echocardiography at the time of second-trimester screening for preeclampsia, showed 
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that women with a mean UtA PI >90
th
 centile (1.25 for this study), had a higher 
prevalence of previously undiagnosed, functionally significant, cardiac defects (4.4%) as 
compared to women with normal mean UtA PI  (0.3%). This risk was particularly higher 
among migrant women 
48
. 
 
Third trimester 
 
 
Technical advice 
• Although uterine artery velocimetry can also be transvaginally examined, the 
commonest method of examination of the uterine arteries Doppler in the third 
trimester is transabdominal  
• The 95
th
 centile of mean uterine artery PI is 1.17 for transabdominal scan at 30-
34 weeks 
 
Recommendation 
• There are currently no randomized trials on the impact of third-trimester 
screening for preeclampsia on maternal fetal and neonatal outcomes; 
consequently, its implementation into routine practice cannot be recommended 
at present.  
• The mean uterine artery PI should be used for prediction for preeclampsia, if this 
is offered in the third trimester 
 
Level of 
evidence: 4 
 
 
Level of 
evidence: 2+ 
 
 
 
 
GPP 
 
 
 
Grade: B 
The standard method for Doppler examination of the uterine arteries Doppler in the third 
trimester is by transabdominal approach, similarly as for the second trimester 
24 41
.  
In a large, multicenter study from the UK, the 90
th
 and 95
th
 centile for mean uterine 
arteries PI between 30
+0
 and 34
+6
 weeks was 1.03 and 1.17, respectively 
49
. Mean 
uterine artery PI >95
th
 centile (5% false-positive rate) alone could predict 54% of 
preeclampsia before 37 weeks and 14% of preeclampsia ≥37 weeks. The corresponding 
rates for mean PI >90
th
 centile (10% false-positive rate) were 68% and 14%, 
respectively, highlighting the poor performance of Doppler studies alone in predicting 
term preeclampsia 
49
. The same group assessed the effectiveness of screening at 35-37 
weeks; uterine artery Doppler alone was a poor predictor for preeclampsia; even when 
combined with maternal factors, the detection rate was 26% for 5% false positive rate, 
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and 37% for 10% false positive rate 
50
. 
Reversed diastolic flow has been sporadically reported in the third trimester and was 
associated with adverse outcome in cases with placental insufficiency, e.g. progress to 
eclampsia, or intrauterine demise 
51 52
. 
 
Longitudinal changes in Doppler indices  
Technical advice 
• Persistently increased uterine artery resistance from first- to second trimester 
may identify women at highest risk for preeclampsia 
Recommendation 
• Given that preventive strategies (e.g. low-dose aspirin) for reducing the risk of 
preeclampsia are effective if started in the first trimester, delaying their 
commencement to assess the evolution of Doppler in the second trimester 
should be avoided 
 
 
Level of 
evidence: 
2++ 
 
 
GPP 
Apart from cross-sectional measurements of Doppler indices, their longitudinal changes 
have also been studied in the prediction of preeclampsia. 
A study sequentially examining uterine artery Doppler at 11-14 and 19-22 weeks 
(N=870) reported that 73% of cases with increased PI at the first trimester normalized at 
the second. Women with persistently increased PI at the first and second trimester were 
at highest risk (37.5%) for adverse pregnancy outcome, i.e. growth restriction or 
hypertensive disorders. In contrast, women with normal PI at the first trimester had a 
95% chance of normal measurements at the second trimester as well, and this was the 
group with the lowest incidence of adverse outcome (5.3%) 
53
. 
Another index that has been tested is the difference between second-trimester PI and 
first-trimester PI, both expressed in MoMs for the corresponding gestational ages. An 
increasing gap between first- and second-trimester PI MoMs, reflecting defective spiral 
artery transformation, appeared to be the most accurate predictor for early (area under 
the curve, AUC 0.85) and preterm (AUC 0.79) preeclampsia 
54
. Another study on 104 
women with increased uterine artery PI at 20-22 weeks reported that the abnormal 
findings persisted at 26-28 weeks in 59.6% of cases; women with persistently increased 
PI had a greater risk for preeclampsia (16% vs. 1%), SGA (32% vs. 1%) and admission 
to a neonatal intensive care unit (26% vs. 4%), compared to women with normalization of 
 
Page 12 of 42
John Wiley & Sons, Ltd.
Ultrasound in Obstetrics and Gynecology
For Peer Review
13 
 
the PI 
55
. 
A problem with sequential assessment of Doppler is that the window of opportunity for 
preventative interventions (i.e. gestational age <16 weeks) is missed, waiting for possible 
changes in a subsequent scan.  
 
Placental volume  
Recommendation 
• Although placental volume and vascularization indices have been tested as 
predictors for preeclampsia, their limited reproducibility and the fact that their 
measurement requires special equipment and is time-consuming limit their use 
for screening 
 
 
GPP 
Shortly after the introduction of three-dimensional ultrasound, first-trimester placental 
volume was tested as a potential predictor of preeclampsia. In one of the initial studies, 
placental volume at 12 weeks was compared to uterine artery Doppler examination at 22 
weeks; the predictive performances of these two methods were 20% and  28%, 
respectively  for preeclampsia without SGA; 31% and 46%, respectively for preeclampsia 
with SGA; and 50% and. 50%, respectively for early preeclampsia 
56
. Similarly, placental 
volume had comparable predictive performance with first-trimester uterine artery mean 
pulsatility index  for preeclampsia (56% vs 50%) and preeclampsia requiring delivery 
before 32 weeks (67% vs. 67%) 
57
. However, these findings have not been confirmed by 
all studies 
58 59
. Three-dimensional placental vascularization indices have also been 
evaluated 
58-62
; however, they can be  affected by  attenuation due to depth and tissue 
interfases,  the use of different ultrasound settings and the lack of a robust reproducibility 
(intra- and interobserver intraclass correlation coefficients <0.48 and <0.66, respectively) 
63
, which all limit their clinical applicability.  
Although a good reproducibility is reported for placental volume calculation 
64 65
, still its 
normal variation is very wide, limiting its clinical applicability; published values for first-
trimester mean placental volume range from 45 to 74 mm
3
 
59 61 64-66
. Moreover, placental 
volume calculation is currently a non-automated measurement subjected to operators 
variations, and can be time-consuming, depending on the number of frames used for 
volume analysis 
67
.  
 
Combined screening strategies  
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Recommendation 
• A combination of maternal factors, maternal arterial blood pressure, uterine 
artery Doppler and placental growth factor (PlGF) at 11-13 weeks appears to be 
the most efficient screening model for identification of women at risk of 
preeclampsia. 
• Given the superiority of combined screening, the use of Doppler cut-offs as a 
standalone screening modality should be avoided if combined screening is 
available. 
• The transabdominal approach should be preferred for calculating first-trimester 
individual patient risk, as most screening algorithms were calculated using 
transabdominal ultrasound.   
 
 
Grade: B 
 
 
Grade: B 
 
 
 
 
GPP 
 
Maternal (history, demographics, cardiovascular and metabolic profile) and placental 
(including uterine artery resistance and biomarkers) risk factors have been identified for 
the development of preeclampsia. Therefore, the current trend in screening involves 
combining the presence or absence of multiple risk factors in order to calculate a 
personalized risk and then act on consequence, in way similar to the screening for 
chromosomal abnormalities 
11
. On a population basis, combined screening aims at 
improving the sensitivity of single marker screening and, at the same time, reducing its 
false positive rate. 
Combined screening has been the topic of approximately 400 PubMed articles as of April 
2018. Multiple studies have shown that women who will develop preeclampsia have, on 
average higher mean arterial pressure 
68
, higher concentrations of maternal serum 
soluble fms-like tyrosine kinase-1 (sFlt-1) 
69 70
 and alpha-fetoprotein (AFP) 
71
, and lower 
concentrations of pregnancy associated plasma protein-A (PAPP-A) 
72
,  placental growth 
factor (PlGF) 
70 73
, along with higher resistance in the uterine arteries 
74
, compared to 
women who did not. For all these predictors, the predictive performance was greater for 
early than for late preeclampsia 
9 70
, and was also greater later in pregnancy than at 11-
13 weeks, i.e. closer to the development of preeclampsia 
68-71 73-75
.  
Data from almost 36000 prospectively followed singleton pregnancies showed that, at a 
false-positive rate of 10%, maternal factors alone (including age, weight, ethnic origin, 
reproductive and medical history, smoking) could predict 49% of preeclampsia <37 
weeks. The addition of PlGF increased this rate to 60%, and combined screening with 
maternal characteristics, uterine artery mean pulsatility index, mean arterial pressure and 
PlGF at 11-13 weeks predicted 75% of preeclampsia <37 weeks and 47% of 
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preeclampsia >37 weeks, 
9
. The same protocol was used in the context of the ASPRE 
trial; in this trial combined screening was followed by randomization to aspirin versus 
placebo in those at high risk. This algorithm combining maternal factors, mean arterial 
pressure, mean uterine artery PI and PlGF achieved 100% detection rate for 
preeclampsia developing <32 weeks, 75% for preeclampsia developing <37 weeks and 
43% for preeclampsia developing ≥37 weeks, for 10% FPR
21 76
. The fetal fraction of cell-
free DNA in the maternal circulation is also significantly associated with maternal and 
fetal factors for preeclampsia, and there is a significant relationship between low fraction 
and increased risk for preeclampsia 
77
; however, its impact on first-trimester screening 
has not been evaluated in prospective studies. 
Similar to the first trimester, a second-trimester model using uterine artery PI, maternal 
factors including BMI, ethnic origin, previous obstetric history, smoking status, type of 
conception, medical history) and mean arterial blood pressure may detect as much as 
100% of women who will develop early preeclampsia for a false positive rate of 10%; the 
sensitivity for late preeclampsia and gestational hypertension is 56.4% and 54.1% 
respectively 
78
.  
In the third trimester, a combination of maternal factors and sFlt-1 measurement may 
predict 83% and 38% of preeclampsia before and after 37 weeks, respectively, for a 
false positive rate of 5%. The corresponding figures for 10% false positive rate are 94% 
and 51%, respectively 
49
. Prior screening in the first and second trimester does not 
further improve prediction accuracy over that of third-trimester alone 
79
. Ethnic origin 
affects the sensitivity and false positive rate of third-trimester prediction, with both being 
higher in women of Afro-Caribbean origin 
80
. Maternal and bioch mical markers become 
more important for the prediction of preeclampsia in late pregnancy. Thus, among 
several potential factors, mean arterial pressure, PlGF and sFlt-1 were the ones 
associated with the prediction of preeclampsia between 30-34 
81
 and 35-37 
82
 weeks. In 
contrast, the addition of uterine artery PI and maternal cardiovascular parameters (total 
peripheral resistance, cardiac output) did not improve the prediction of preeclampsia 
after 35-36 weeks 
83
. The sFlt-1/PlGF ratio as a standalone marker can predict more 
than 75% of the cases who will develop preeclampsia within 4 weeks, but its sensitivity is 
significantly higher at 31-34 than at 35-37 weeks (false positive rates 1.7% vs. 9.6%, 
respectively) 
84
. 
A common concern with combined screening models is that they may perform differently 
when prospectively applied in populations different than the ones they were derived from 
85
. To this end, the performance of the combined screening model used for the ASPRE 
trial (maternal factors, mean arterial pressure, mean uterine artery PI, placental growth 
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factor) was practically identical to the dataset used for development of the model 
9 76
. In 
fact, this strategy was found to be considerably more efficient for the prediction of early 
preeclampsia than the history-based screening policies recommended by both the 
American College of Obstetricians and Gynecologists and the UK National Institute for 
Health and Care Excellence
22 86
. 
 
ASSESSMENT OF MATERNAL HEMODYNAMICS  
Recommendation 
• Despite the fact that maternal hemodynamic assessment may be of value in 
prediction of preeclampsia, there are still few data to support their routine 
implementation in clinical practice as standalone tests. 
 
 
 
GPP 
Cardiovascular adaptation plays a critical role in the hemodynamic changes observed in 
normal pregnancy. Failure of this adaptation, or possibly subclinical pre-pregnancy 
cardiovascular dysfunction, have been associated with the risk of developing 
preeclampsia 
87-89
. Women who develop preeclampsia have pre-pregnancy 
cardiovascular risk factors, demonstrate increased arterial stiffness and impaired cardiac 
function at the time of the clinical diagnosis, as well as several weeks before the clinical 
onset of the pathology and several months after the incident pregnancy 
90-101
. The 
cardiovascular implications of pre-eclampsia appear to continue in the long-term, as 
shown by both by increased frequency of prolonged subclinical impairment of systolic 
biventricular 
102
 and endothelial function 
103
, and by the increas d risk of cardiovascular 
morbidity later in life 
104-106
. The hazard ratio for developing cardiovascular disease later 
in life is as high as 5.4 in women who had severe pre-eclampsia/eclampsia 
105
. 
Moreover, compared to women with no recurrent disease, women who develop recurrent 
preeclampsia in a subsequent pregnancy tend to have altered cardiovascular 
parameters between pregnancies, which may hinder their normal adaptation in the next 
pregnancy 
107
. 
 
The simplest hemodynamic parameter with established value in the context of combined 
screening is maternal mean arterial pressure 
9 76 78 108
. Additionally, arterial stiffness can 
be estimated by ultrasound and this parameter has been found to differ significantly in 
women with preeclampsia from women with normal pregnancies. In a systematic review 
of 23 studies evaluating arterial stiffness in association with hypertensive disease of 
pregnancy, women with preeclampsia had elevated arterial stiffness both during and 
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after pregnancy, and to a greater extent than in gestational hypertension (GH) 
90
. 
Interestingly, more severe preeclampsia is associated with greater arterial stiffness 
90
. 
Both pulse wave analysis and the augmentation index have also been observed to be 
higher in the sub-clinical stage (as early as 11 weeks) in women who will develop 
preeclampsia 
91 92
. Cross-sectional and longitudinal studies have demonstrated that 
arterial stiffness indices could be used as a screening test, as early as 11 weeks’ 
gestation, to predict subsequent development of early and late-onset pre-eclampsia, 
especially when combined with other maternal variables such as central systolic blood 
pressure 
91 92
. Lower flow-mediated dilatation has been reported in the first and second 
trimesters among high-risk women who subsequently developed preeclampsia 
109 110
.  
 
Cardiac output was significantly higher at 11-13 weeks in women who later developed 
preeclampsia or gestational hypertension, compared to uncomplicated pregnancies 
94
. 
When combined with maternal variables, for a 10% false-positive rate, the detection 
rates were 43.4% for all types preeclampsia, 52% for preeclampsia without a small for 
gestational age foetus, and 23.3% for gestational hypertension 
94
. Women who 
subsequently develop preeclampsia have evidence of left ventricular concentric 
remodelling at mid-gestation 
97
. 
 
Despite the fact that maternal hemodynamics are promising screening markers of 
preeclampsia, a combined approach taking into account maternal characteristics and 
biochemical markers is required to reach a clinically useful prediction model. Meanwhile, 
as assessment of maternal hemodynamics is increasingly being performed in 
preeclampsia studies, it is imperative that relevant devices and techniques are 
appropriately used in pregnant populations 
111
. 
 
 
WHAT TO DO AFTER SCREENING  
Recommendation 
• There is convincing evidence that low-dose aspirin can significantly decrease the 
risk for development of early preeclampsia, when commenced at the time of first-
trimester screening 
 
 
Grade: A 
First trimester 
Currently, the American College of Obstetricians and Gynecologists
112
, the UK National 
Institute for Health and Care Excellence (NICE) 
113
 and the Society of Obstetricians and 
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Obstetricians of Canada 
114
, among others, recommend administering low-dose aspirin 
to women at risk for placental insufficiency, commencing before 16 weeks. 
Most of the studies on which current recommendations are based, classified women as 
high-risk based on historical or medical factors rather than using current screening 
methods (i.e. maternal factors, Doppler and biochemistry). In 2017, the multicenter 
ASPRE trial was reported. In this study, 1776 women at high risk for preeclampsia based 
on first-trimester combined screening were randomized to either aspirin 150 mg at 
bedtime or placebo 
10
. The dose of 150 mg was selected in line with evidence that a 
significant proportion (10-30%) of patients show aspirin resistance at lower doses 
115
, 
and in vitro data showing that the optimal dose to improve trophoblast function is the 
equivalent of 150mg in vivo 
116
. Bedtime administration was based on data indicating the 
presence of a diurnal effect in response to aspirin, with optimal effectiveness for bedtime 
administration 
117
. The ASPRE trial found that aspirin reduced the risk for preeclampsia 
before 37 weeks by 62% (from 4.3% to 1.6%). Aspirin also reduced the risk of 
preeclampsia before 34 weeks by 82%, but this effect did not reach statistical 
significance due to the small absolute rates (0.4% vs. 1.8%) 
10
. The beneficial effect of 
aspirin appeared to depend on the degree of compliance, with the greatest risk reduction 
observed for compliance ≥90% 
118
.  
First-trimester screening and intervention with aspirin appears to be cost-effective, 
combining the prevention of a significant proportion of early onset cases with cost 
savings for the health system 
119
. 
 
Second trimester  
Second-trimester prediction appears to be equally or more sensitive 
70 78
 as prediction in 
the first-trimester, but its value is limited by the lack of effective interventions at this 
gestational stage. While aspirin commenced in the first trimester appears to reduce the 
development of preeclampsia 
120 121
, the same intervention seems ineffective when 
started after 20 weeks 
120
. Although it is too late to prevent the development of 
preeclampsia after second trimester prediction, its results can still be useful in guiding 
further follow-up 
122 123
. However, the clinical impact of intensified follow-up is yet to be 
proven. A Spanish trial (N=11667) randomized women who attended routine second-
trimester scan to Doppler or non-Doppler groups. It was found that Doppler velocimetry 
identified 60% of the women who developed preeclampsia, but the intensification of their 
care did not result in better short-term maternal and perinatal outcomes compared to 
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women who had not a second-trimester Doppler examination at second-trimester scan 
124
. 
Third trimester 
Third-trimester prediction can identify the great majority of women who will develop 
preeclampsia in the subsequent weeks 
80 125
. This policy has been described as part of a 
longitudinal risk-assessment scheme mainly focused on early detection, which involves 
detailed screening in the first trimester for stratification for all major obstetric 
complications, and then contingent screening based on the risk reassessment at each 
visit 
125 126
. The validation and audit of this strategy is a subject of ongoing research. 
 
 
WHAT TO DO IN MULTIPLE PREGNANCIES  
Recommendation 
• Due to increased placental mass in twin pregnancies resulting in a lower mean 
resistance in the uterine arteries, twin-specific reference ranges should be used 
for Doppler examination, if available. 
• Combined screening (maternal factors, uterine artery PI, mean arterial pressure, 
PlGF) the algorithm for singletons can be also used in twins and it can predict 
more than 95% of women who will develop preeclampsia. The examiner should 
be aware that this is achieved at the cost of 75% screen-positive rate.  
 
 
Grade: B 
 
 
 
Grade: B 
Twin pregnancy is a risk factor for obstetric complications, including preeclampsia 
127
. 
The increased placental mass in twin pregnancies results in a lower mean uterine artery 
resistance compared to singleton pregnancies at the same gestational age 
128-130
. As a 
result, using reference ranges for singleton pregnancies, which are higher than those for 
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twins, may result in reduced sensitivity of Doppler screening. A study comparing the two 
approaches reported that twin-specific ranges resulted in a sensitivity of 36.4%, for 12% 
false positive rates; if the standard cutoffs for singleton pregnancies were used, the 
sensitivity would be 18% for 1.7% false positive rate 
130
. 
Chorionicity could theoretically have an impact on the extent of uterine hemodynamics 
adaptation, as mono-and dichorionic twins have different placental masses and 
architecture. Indeed, a survival-time model analysis calculated that, for a reference 
population standardized for maternal characteristics, the risk for preeclampsia <37 
weeks’ gestation is 9.0% for dichorionic twins and 14.2% for monochorionic twins, as 
compared to 0.6% for singleton pregnancies 
131
. A study in the first trimester reported 
higher uterine artery resistance in monochorionic compared to dichorionic twins; in fact 
monochorionic twins had similar resistance as singleton fetuses 
132
.  
First-trimester uterine artery mean PI is already lower in twin pregnancies 
128 132
. 
Excluding cases with subsequent twin-to-twin transfusion syndrome, first-trimester mean 
uterine artery PI was 46% higher in twin pregnancies that developed early-onset 
preeclampsia and 22% higher in those developing late preeclampsia, compared to 
uncomplicated twin pregnancies 
128
.  
As in the first trimester, second-trimester mean uterine artery PI is lower in twin 
compared to singleton pregnancies. In a study of dichorionic twin pregnancies from 17 to 
38 weeks, the 95
th
 centile for the mean uterine artery PI, measured transabdominally, 
was 1.21 at 21 weeks, 1.16 at 22 weeks, 1.12 at 23 weeks and 1.09 at 24 weeks 
133
. 
Using the transvaginal approach, a cut-off of 1.5 for mean UtA PI at 22-24 weeks, had 
33.3% sensitivity for preeclampsia, for 3.3% false positive rate (monochorionic and 
dichrorionic twins) 
129
.  
As in singleton pregnancies, combined screening has a better performance than each of 
its individual components. A recent study assessed first-trimester screening with 
maternal factors, uterine artery PI, mean arterial pressure, PAPP-A and PlGF and found 
that the detection rate of preeclampsia requiring delivery before 32 and 37 weeks was 
100% and 99%, respectively, at the cost of a screen-positive rate of 75%. The use of 
twin-specific charts resulted in only a minor increase in the performance of the model
131
. 
 
THE USE OF ULTRASOUND IN A PATIENT WITH ESTABLISHED 
PREECLAMPSIA 
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Deteriorating fetal status is one of the indication for delivery in preeclampsia; therefore, 
close fetal surveillance is commonly needed until delivery 
134 135
. Ultrasound is obviously 
the cornerstone for fetal assessment.  However, there are currently no randomized 
controlled trials, and therefore the optimal surveillance strategy and its impact on 
outcome need to be determined. The three main components for fetal evaluation in 
clinical practice are: 1) B-mode ultrasound, 2) Doppler, and 3) fetal heart rate 
monitoring.
136
. 
 
Recommendations 
• Given that fetal deterioration is an indication for delivery in established 
preeclampsia, fetal status should be regularly assessed in these patients. 
• The sonographic follow-up in pregnancies affected by preeclampsia includes 
assessment of fetal growth, biophysical profile and fetal Doppler studies. 
• As there are currently no randomized controlled trials, the components, 
frequency, and impact of ultrasound surveillance in pregnancies affected by 
preeclampsia are yet to be determined. 
• Examination of fetal biometry, amniotic fluid volume, uterine-, umbilical- and 
middle cerebral artery PI and cerebroplacental ratio, as well as placenta 
visualization to exclude abruption should be considered in women presenting 
with headache, abdominal pain, bleeding and reduced fetal movements.  
• The same tests should be considered for women admitted for or with suspected 
preeclampsia, as well as for severe preeclampsia or HELLP syndrome. 
  
 
GPP 
 
GPP 
 
GPP 
 
 
 
GPP 
 
 
 
GPP 
 
Preeclampsia is commonly associated with fetal growth restriction, and these fetuses 
tend to be delivered earlier and deteriorate faster than growth-restricted fetuses of 
normotensive mothers 
137
. Therefore, the identification and follow-up of fetal growth 
restriction is of paramount importance for the optimization of perinatal outcome in 
preeclampsia.  
 
B-mode ultrasound  
Biometry  
Fetal biometry can be assessed to identify a small-for-gestational-age fetus; and to 
predict small-for-gestational-age newborns 
138
.  
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Amniotic fluid index  
The amount of amniotic fluid can be assessed by the amniotic fluid index (AFI) or by the 
maximum vertical pocket (MVP): MVP <2 cm and/or AFI <5 cm are considered as cut-off 
values for the diagnosis of reduced amniotic fluid or oligohydramnios 
139 140
. Compared to 
AFI, measurement of MVP may result in fewer interventions without increasing adverse 
perinatal outcomes 
141
. 
Fetal movements  
As part of the fetal biophysical profile, fetal breathing movements, body / limb 
movements and muscular tone (i.e. extension and flexion of a fetal extremity or an 
opening and closing of the hand) should be observed 
142
. These three components, plus 
the presence/absence of oligohydramnios and fetal heart rate monitoring constitute the 
fetal biophysical profile (BPP). Positive findings for each component are assigned a 
value of 2 with the total BPP ranging from 0 to 10. A BPP score of ≥8 is considered to be 
a normal BPP and a manifestation of fetal well-being. BPP of 6 is a non-conclusive 
result, and the test should be repeated. A BPP ≤4 is a non-reassuring fetal test and 
delivery should be considered 
143 144
. BPP testing is mostly used in the USA, whereas 
clinical management in Europe is mostly based on Doppler examination. There are no 
data for the comparative cost-effectiveness of the two methods.  
Placenta  
Visualization of the placenta might help to exclude signs suggestive of severe 
preeclampsia, such as a thickened placenta with diffuse echogenicity most probably due 
to edema, a thin placenta with reduced vascularization,
145 146
 or the presence of cystic 
regions suggestive of infarctions or hematomas.
147 148
 Women with preeclampsia are at 
risk of partial or total abruption; therefore, evaluation of the interphase 
placenta/myometrium is important.
149 150
. Sonographic findings related to placental 
abruption include retroplacental hematoma (hyperechoic, isoechoic, hypoechoic), 
preplacental hematoma, increased placental thickness and echogenicity, sub-chorionic 
collection and marginal collection of blood. However, the sensitivity of ultrasound in 
diagnosing placental abruption is poor, as approximately 50-75% of these cases may be 
missed by scan 
151 152
. Chronic abruption, which may be seen as a retroplacental 
sonolucent area on ultrasound, and oligohydramnios sequence can develop in 
preeclamptic patients.
153
. 
Doppler  
The four Doppler territories commonly examined for fetal and maternal evaluation are 1) 
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umbilical artery (UA), 2) middle cerebral artery, 3) ductus venosus, and 4) uterine 
arteries. 
Briefly, absent or reversed end-diastolic (A/RED) velocities in the umbilical artery (UmA) 
are highly associated with perinatal morbidity/mortality 
154 155
. A reduced middle cerebral 
artery PI (MCA-PI) <10
th
 percentile is a sign of brain vasodilatation and has been 
associated with emergency cesarean delivery due to non-reassuring fetal heart rate 
monitoring in growth restricted fetuses 
156-158
. A cerebro-placental ratio (CPR) below the 
10
th
 percentile is considered to be a sign of hemodynamic redistribution, can be 
observed even before the UmA is affected and is an indicator for close fetal surveillance 
159-161
. Reversed a-wave in the ductus venosus is a strong manifestation of fetal cardiac 
deterioration and is associated with a high risk of perinatal mortality and severe neonatal 
morbidity 
162 163
. The results of the TRUFFLE trial provide insight on the follow-up of 
growth-restricted fetuses in preeclampsia, as most of its participants had preeclampsia at 
enrollment, or developed it during their follow-up. It was found that the optimal long-term 
outcome for growth-restricted fetuses with abnormal umbilical artery flow is achieved 
when delivery is postponed until the a-wave in the ductus venosus becomes reversed, 
unless reduced short-term variability on non-stress test is observed meanwhile, which 
also prompts immediate delivery 
137 164 165
. Increased resistance in the uterine artery flow 
indicates defective spiral artery transformation and is not useful as an indication for 
delivery. 
Guidelines for fetal Doppler evaluation have been published previously and further 
details of Doppler evaluation are beyond the scope of this guideline
16
.  
.  
Technical advice 
• Administration of antihypertensive drugs is not associated with significant 
changes in maternal and fetal Doppler indices 
• Antenatal corticosteroids are associated with a transient decrease in the 
vascular resistance in the umbilical arteries and ductus venosus 
• The data about a potential effect of magnesium sulfate on maternal and fetal 
Doppler indices are inconclusive 
 
 
Level of 
evidence: 2+ 
Level of 
evidence: 2+ 
Level of 
evidence: 2- 
No changes in the Doppler waveforms of the uterine and umbilical arteries have been 
reported associated with the use of labetalol, nifedipine or hydralazine 
166-169
. However, 
Grzesiak et al.
170
 and Lima et al.
171
 reported a mild reduction in the MCA-PI after 
administration of nifedipine with no alteration in the other vascular territories. Methyldopa 
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also has no effect on the uterine artery resistance in patients with gestational 
hypertensive disease 
172
.  
The effect of antenatal corticosteroids in the fetal circulation has been extensively 
documented. A transient reduction in vascular resistance and in the PI of the umbilical 
artery and the ductus venosus is generally observed. Absent or reversed end-diastolic or 
atrial velocities generally improve after the administration of corticosteroids; this effect 
can last for 48-72 hours, but it can be longer in some fetuses. Some authors also 
reported a mild reduction in the MCA-PI; however, no effect of steroids on the uterine 
arteries’ Doppler waveform has been reported 
173-176
 
There is no consensus regarding the effect of magnesium sulfate on fetal 
hemodynamics. Some authors reported a reduction in the PI or in the RI of the umbilical, 
uterine, and MCA arteries after the administration of magnesium sulfate;
177-179
 but others 
have not seen such an effect.
180
 
AREAS OF FUTURE RESEARCH  
Recommendation 
• Doppler studies need to fulfill quality criteria, including prospective data 
collection, specific scan for research purposes and examination of consecutive 
patients (i.e. non-opportunistic) recruitment. 
 
 
Grade: C 
Doppler examination of maternal and fetal vessels has been used for about two decades 
with a significant positive impact on maternal and fetal health. However, both older and 
newer Doppler studies may be biased, for different reasons. Older studies were 
performed using ultrasound machines of lower imaging detail than the ones used now, 
and is not certain whether their results would be identical if newer ultrasound technology 
had been used. Newer Doppler studies were performed at a time where the value of 
Doppler was already established and this may have resulted in two forms of bias. The 
first is intention-to-treat bias, i.e. the Doppler measurements may have affected the 
management, hence the natural history, of the condition they were only suppose to 
diagnose. The second is the expected value bias, i.e. as normal ranges of Doppler 
measurement were becoming available, many examiners might subconsciously have 
pulled their measurements towards the expected normal range; therefore any 
retrospective study using these data may have been biased. A recent systematic 
review
181
 showed that the vast majority of Doppler studies suffers from methodological 
limitations and proposes a set of criteria, which should be applied in future high-quality 
studies. These criteria involve, among others, prospective data collection, specific scan 
for research purposes and examination of consecutive patients (i.e. non-opportunistic) 
recruitment 
181
. 
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Summary of recommendations  
Relevant information available to the examiner 
• Examiners involved in screening for preeclampsia should have up-to-date knowledge 
regarding major risk factors for preeclampsia (Good Practice Point) 
 
Which Doppler index to use 
• The pulsatility index (PI) is the index that should be used for the examination of the 
uterine artery resistance in the context of preeclampsia screening (Grade B 
recommendation) 
 
First-trimester screening for preeclampsia 
• Maternal factors can affect uterine artery PI. Therefore, whenever feasible, inclusion of 
uterine artery PI in a multifactorial screening model should be preferred over its use as 
a standalone test with absolute cut-offs (Grade B recommendation) 
• The mean uterine artery PI should be the Doppler index used for screening in the first 
trimester (Grade B recommendation) 
 
Second-trimester screening for preeclampsia 
• The mean uterine artery PI should be used for screening in the second trimester. In 
case of a unilateral placenta, a unilaterally increased PI does not appear to increase 
the risk for preeclampsia if the mean PI is within normal limits (Grade B 
recommendation) 
 
Third-trimester screening for preeclampsia 
• There are currently no randomized trials on the impact of third-trimester screening for 
preeclampsia on maternal, fetal and neonatal outcomes; consequently, its 
implementation into routine pratice cannot be recommended at present. (Good 
Practice Point) 
• The mean uterine artery PI should be used for prediction for preeclampsia, if this is 
offered in the third trimester (Grade B recommendation) 
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Longitudinal changes in Doppler indices 
• Regarding sequential Doppler examinations, preventive strategies for reducing the risk 
of preeclampsia are effective if started in the first trimester; therefore, delaying the 
commencement of preventive strategies to assess the evolution of Doppler in the 
second trimester should be avoided (Good Practice Point) 
Placental volume 
• Although placental volume and vascularization indices have been tested as predictors 
for preeclampsia, their limited reproducibility and the fact that their measurement 
requires special equipment and is time-consuming limit their use for screening (Good 
Practice Point) 
Combined screening strategies 
• A combination of maternal factors, maternal arterial blood pressure, uterine artery 
Doppler and placental growth factor (PlGF) at 11-13 weeks appears to be the most 
efficient screening model for identification of women at risk of preeclampsia (Grade B 
recommendation). 
• Given the superiority of combined screening, the use of Doppler cut-offs as a 
standalone screening modality should be avoided if combined screening is available 
(Grade B recommendation). 
• The transabdominal approach should be preferred for calculating first-trimester 
individual patient risk, as most screening algorithms were calculated using 
transabdominal ultrasound (Good Practice Point).   
 
Assessment of maternal hemodynamics 
• Despite the fact that maternal hemodynamic assessment may be of value in prediction 
of preeclampsia, there are still few data to support their routine implementation in 
clinical practice as standalone tests (Good Practice Point) 
 
What to so after screening 
• There is convincing evidence that low-dose aspirin can significantly decrease the risk 
for development of early preeclampsia, when commenced at the time of first-trimester 
screening (Grade A recommendation). 
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What to do in multiple pregnancies 
 
• Due to increased placental mass in twin pregnancies resulting in a lower mean 
resistance in the uterine arteries, twin-specific reference ranges should be used for 
Doppler examination, if available (Grade B recommendation). 
• Combined screening (maternal factors, uterine artery PI, mean arterial pressure, PlGF) 
the algorithm for singletons can be also used in twins and it can predict more than 95% 
of women who will develop preeclampsia. The examiner should be aware that this is 
achieved at the cost of 75% screen-positive rate (Grade B recommendation).  
 
The use of ultrasound in a patient with established preeclampsia 
• Given that fetal deterioration is an indication for delivery in established preeclampsia, 
fetal status should be regularly assessed in these patients (Good Practice Point). 
• The sonographic follow-up in pregnancies affected by preeclampsia includes 
assessment of fetal growth, biophysical profile and fetal Doppler studies (Good 
Practice Point). 
• As there are currently no randomized controlled trials, the components, frequency, and 
impact of ultrasound surveillance in pregnancies affected by preeclampsia are yet to 
be determined (Good Practice Point). 
• Examination of fetal biometry, amniotic fluid volume, uterine-, umbilical- and middle 
cerebral artery PI and cerebroplacental ratio, as well as placenta visualization to 
exclude abruption should be considered in women presenting with headache, 
abdominal pain, bleeding and reduced fetal movements (Good Practice Point).  
• The same tests should be considered for women admitted for or with suspected 
preeclampsia, as well as for severe preeclampsia or HELLP syndrome (Good Practice 
Point) 
 
Areas of future research  
• Doppler studies need to fulfill quality criteria, including prospective data collection, 
specific scan for research purposes and examination of consecutive patients (i.e. non-
opportunistic) recruitment (Grade C recommendation). 
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Classification of evidence levels 
 
1++ High-quality meta-analyses, systematic reviews of randomised controlled trials or randomised 
controlled trials with a very low risk of bias 
1+ Well-conducted meta-analyses, systematic reviews of randomised controlled trials or randomised 
controlled trials with a low risk of bias 
1- Meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials 
with a high risk of bias 
2++ High-quality systematic reviews of case–control or cohort studies or high-quality case–control or 
cohort studies with a very low risk of confounding, bias or chance and a high probability that the 
relationship is causal 
2+ Well-conducted case–control or cohort studies with a low risk of confounding, bias or chance and 
a moderate probability that the relationship is causal 
2- Case–control or cohort studies with a high risk of confounding, bias or chance and a significant 
risk that the relationship is not causal 
3 Non-analytical studies, e.g. case reports, case series 
4 Expert opinion 
 
Grades of recommendations 
 
A At least one meta-analysis, systematic review or randomised controlled trial rated as 1++ and 
directly applicable to the target population; or a systematic review of randomised controlled trials or a 
body of evidence consisting principally of studies rated as 1+ directly applicable to the target population 
and demonstrating overall consistency of results 
B A body of evidence including studies rated as 2++ directly applicable to the target population, and 
demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1+ 
C A body of evidence including studies rated as 2+ directly applicable to the target population and 
demonstrating overall consistency of results; or extrapolated evidence from studies rated as 2++ 
D Evidence level 3 or 4; or extrapolated evidence from studies rated as 2+ 
GPP Recommended best practice based on the clinical experience of the guideline development group 
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Legend for figure 
Figure 1. Transabdominal examination of first-trimester uterine artery waveform. The loop of the uterine 
artery is located at a paracervical section, and at least three identical waveforms are recorded with an 
insonation angle as close to 0° as possible. 
Page 41 of 42
John Wiley & Sons, Ltd.
Ultrasound in Obstetrics and Gynecology
For Peer Review
  
 
 
Figure 1. Transabdominal examination of first-trimester uterine artery waveform in the first trimester. The 
loop of the uterine artery is located at a paracervical section, and at least three identical waveforms are 
recorded with an insonation angle as close to 0° as possible.  
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